PLAU and neoplasm: Hence, IC3-PA achieves high tumor-specificity by simultaneously targeting three distinct cancer markers, i.e. tumor-associated proteases MMPs and uPA, as well as the CMG2 receptor found on cancer cells (Figure 1).